세계의 다라투무맙(다잘렉스) 시장 보고서(2025년) : 역학, 파이프라인 분석, 시장 인사이트 및 예측

Daratumumab Or Darzalex Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

US $ 4,490 ￦ 6,482,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,370,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,257,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

다라투무맙(다잘렉스) 시장 규모는 향후 몇 년간 급속한 성장을 기록할 것으로 예상됩니다. 예측 기간의 성장은 임상적 증거의 증가, 초기 치료 단계에서의 채택 증가, 생물학적 제제에 대한 수요 증가, 환자 인식 수준 향상, 혈액암 발병률 증가, 만성 질환의 유병률 증가에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 기술 발전, 신제품 출시, 제품 및/또는 서비스 제공, 파트너십, 합병 및 인수, 방사선 기술의 발전, 협업 등이 있습니다.

골수암의 발병률이 증가함에 따라 앞으로 다라투무맙(다잘렉스) 시장의 성장이 촉진될 것으로 예상됩니다. 다발성 골수종 및 백혈병과 같은 골수암은 골수에서 시작되어 비정상적인 혈액 세포를 생성하여 정상적인 신체 기능을 방해합니다. 골수암의 발병률 증가는 인구 고령화, 진단 방법의 발전, 환경, 생활 습관 및 유전적 요인의 영향과 같은 요인에 기인할 수 있습니다. 다라투무맙(다잘렉스)은 골수 내 비정상적인 플라즈마 세포를 표적화하고 제거하여 다발성 골수종을 치료합니다. 예를 들어, 2024년 1월 미국 암 협회는 림프종 89,190건과 골수종 35,780건을 예측했으며, 이는 2022년의 8만 9,010건과 3만 4,470건과 비교됩니다. 골수암 발병률의 이러한 증가는 다라투무맙(다잘렉스) 시장의 확장을 촉진하고 있습니다.

생물학적 제제 및 표적 치료법의 채택이 증가함에 따라 다라투무맙(다잘렉스) 시장의 성장이 더욱 가속화될 것으로 예상됩니다. 표적 치료는 의약품이나 기타 물질을 사용하여 암과 같은 질병의 진행에 관여하는 분자를 구체적으로 식별하고 공격합니다. 생물학적 제제 및 표적 치료의 사용이 증가하는 것은 만성 질환의 유병률 증가와 정밀 의학의 발전에 의해 촉진되고 있으며, 이를 통해 보다 개인화되고 효과적인 치료가 가능해지고 있습니다. 다라투무맙은 다발성 골수종에서 악성 혈장 세포에 고도로 발현되는 단백질인 CD38을 특이적으로 표적으로 하는 표적 치료제의 하나입니다. 예를 들어, 2023년 12월, ATTC(Advanced Therapy Treatment Centers)는 2022년에 첨단 치료에 대한 연간 투자가 31% 증가했으며, 영국이 전 세계 상업용 첨단 치료 의약품(ATMP) 임상 시험의 14%를 차지했다고 보고했습니다. 생물학적 제제 및 표적 치료의 채택이 증가하면서 다라투무맙(다잘렉스) 시장이 성장하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 바이오의약품 시장에서의 제품 특성

• 분자 유형
• 투여경로(ROA)
• 작용기전(MOA)
• 안전성과 유효성

제4장 시장 동향과 전략

제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제6장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 다라투무맙(다잘렉스) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 다라투무맙(다잘렉스) 시장 : 성장률 분석
• 세계의 다라투무맙(다잘렉스) 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 다라투무맙(다잘렉스) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 다라투무맙(다잘렉스) : 전체 시장 규모(TAM)

제7장 세계 시장의 가격 분석과 예측

제8장 시장 세분화

• 세계의 다라투무맙(다잘렉스) 시장 : 약제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 100mg 주사제
• 400mg 주사제
• 세계의 다라투무맙(다잘렉스) 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 약국
• 병원
• 기타
• 세계의 다라투무맙(다잘렉스) 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 여포성 림프종
• 맨틀 세포 림프종
• 다발성 골수종
• 확산성 대세포형 B세포 림프종
• 기타

제9장 임상적응증 세계 시장 역학

• 약제의 부작용
• 임상적응증의 발병률과 유병률

제10장 지역별, 국가별 분석

• 세계의 다라투무맙(다잘렉스) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 다라투무맙(다잘렉스) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 경쟁 구도와 기업 프로파일

• 다라투무맙(다잘렉스) 시장 : 경쟁 구도
• 다라투무맙(다잘렉스) 시장 : 기업 프로파일
  • Genmab A/S
  • Janssen BIoTech Inc.

제29장 세계 시장 : 파이프라인 분석

제30장 세계 시장 경쟁 벤치마킹과 대시보드

제31장 주요 인수합병(M&A)

제32장 최근 시장 동향

제33장 시장의 잠재력이 높은 국가, 전략

• 다라투무맙(다잘렉스) 시장(2029년) : 새로운 기회를 제공하는 국가
• 다라투무맙(다잘렉스) 시장(2029년) : 새로운 기회를 제공하는 부문
• 다라투무맙(다잘렉스) 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제34장 부록

HBR

영문 목차

영문목차

Daratumumab, also known by its brand name Darzalex, is a monoclonal antibody used in the treatment of certain cancers, primarily multiple myelomas. It is designed to target and bind to CD38, a protein highly expressed on the surface of multiple myeloma cells, as well as other malignant and normal immune cells.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of daratumumab (Darzalex) are 100 mg injection and 400 mg injection. The 100 mg injection refers to a dose of the medication administered via injection, containing 100 milligrams (mg) of the active ingredient. These drugs are distributed through various channels, including pharmacies, hospitals, and other medical distribution networks. They are used in the treatment of conditions such as follicular lymphoma, mantle cell lymphoma, multiple myeloma, diffuse large B-cell lymphoma, and others.

The daratumumab or darzalex market research report is one of a series of new reports from The Business Research Company that provides daratumumab or darzalex market statistics, including daratumumab or darzalex industry global market size, regional shares, competitors with a daratumumab or darzalex market share, detailed daratumumab or darzalex market segments, market trends and opportunities, and any further data you may need to thrive in the daratumumab or darzalex industry. This daratumumab or darzalex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The daratumumab or darzalex market size is expected to see rapid growth in the next few years. It will grow to $8,189.4 million in 2029 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing clinical evidence demonstrating, rising adoption in earlier treatment lines, increasing the demand for biologics, increasing patient awareness levels, growing incidence of blood cancer, and rising prevalence of chronic diseases. Major trends in the forecast period include technological advancements, new product launches, offerings of products and/or services, partnerships, mergers and acquisitions, advancements in radiation technologies, and collaborations.

The increasing incidence of bone marrow cancers is expected to drive the growth of the daratumumab (Darzalex) market in the future. Bone marrow cancers, such as multiple myeloma and leukemia, begin in the bone marrow, causing abnormal blood cell production that disrupts normal body functions. The rise in bone marrow cancer cases can be attributed to factors like an aging population, better detection methods, and environmental, lifestyle, and genetic influences. Daratumumab (Darzalex) is used to treat multiple myeloma by targeting and eliminating abnormal plasma cells in the bone marrow. For example, in January 2024, the American Cancer Society projected 89,190 lymphoma cases and 35,780 myeloma cases, compared to 89,010 and 34,470 in 2022, respectively. This rise in bone marrow cancer incidence is driving the expansion of the daratumumab (Darzalex) market.

The growing adoption of biologics and targeted therapies is expected to further fuel the growth of the daratumumab (Darzalex) market. Targeted therapies use drugs or other substances to specifically identify and attack molecules involved in disease progression, such as cancer. The increasing use of biologics and targeted therapies is driven by the rising prevalence of chronic diseases and advancements in precision medicine, which allow for more personalized and effective treatments. Daratumumab is part of these targeted therapies, as it specifically targets CD38, a protein highly expressed on malignant plasma cells in multiple myeloma. For instance, in December 2023, the Advanced Therapy Treatment Centers (ATTC) reported a 31% increase in annual investments in advanced therapies in 2022, with the UK accounting for 14% of global commercial advanced therapy medicinal product (ATMP) clinical trials. This growing adoption of biologics and targeted therapies is contributing to the growth of the daratumumab (Darzalex) market.

A key trend in the daratumumab (Darzalex) market is the shift toward early intervention strategies, such as combination therapies, to enhance the effectiveness of treating multiple myeloma and other cancers. Combination therapies use two or more drugs with different mechanisms of action to improve efficacy, reduce resistance, and potentially lower adverse effects compared to monotherapy. For example, in July 2024, Johnson & Johnson received U.S. FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplant (ASCT). This approval introduces a quadruplet therapy option for patients at initial diagnosis, potentially improving treatment outcomes.

Major players operating in the daratumumab or darzalex market are Genmab A/S, Janssen Biotech Inc.

North America was the largest region in the daratumumab or darzalex market in 2024. The regions covered in daratumumab or darzalex report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the daratumumab or darzalex market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The daratumumab or darzalex market consists of sales of darzalex faspro, darzalex injection, dexamethasone, and pomalidomide. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Daratumumab Or Darzalex Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on daratumumab or darzalex market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for daratumumab or darzalex ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The daratumumab or darzalex market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: 100Mg Injection; 400Mg Injection
• 2) By Distribution Channel: Pharmacies; Hospital; Other Distribution Channels
• 3) By Application: Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma; Diffuse Large B Cell Lymphoma; Other Applications
• Companies Mentioned: Genmab A/S; Janssen Biotech Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Daratumumab Or Darzalex Market Characteristics

3. Daratumumab Or Darzalex Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Daratumumab Or Darzalex Market Trends And Strategies

5. Daratumumab Or Darzalex Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Daratumumab Or Darzalex Growth Analysis And Strategic Analysis Framework

• 6.1. Global Daratumumab Or Darzalex PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Daratumumab Or Darzalex Market Growth Rate Analysis
• 6.4. Global Daratumumab Or Darzalex Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Daratumumab Or Darzalex Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Daratumumab Or Darzalex Total Addressable Market (TAM)

7. Global Daratumumab Or Darzalex Market Pricing Analysis & Forecasts

8. Daratumumab Or Darzalex Market Segmentation

• 8.1. Global Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 100Mg Injection
• 400Mg Injection
• 8.2. Global Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacies
• Hospital
• Other Distribution Channels
• 8.3. Global Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Multiple Myeloma
• Diffuse Large B Cell Lymphoma
• Other Applications

9. Global Daratumumab Or Darzalex Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Daratumumab Or Darzalex Market Regional And Country Analysis

• 10.1. Global Daratumumab Or Darzalex Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Daratumumab Or Darzalex Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Daratumumab Or Darzalex Market

• 11.1. Asia-Pacific Daratumumab Or Darzalex Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Daratumumab Or Darzalex Market

• 12.1. China Daratumumab Or Darzalex Market Overview
• 12.2. China Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Daratumumab Or Darzalex Market

• 13.1. India Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Daratumumab Or Darzalex Market

• 14.1. Japan Daratumumab Or Darzalex Market Overview
• 14.2. Japan Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Daratumumab Or Darzalex Market

• 15.1. Australia Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Daratumumab Or Darzalex Market

• 16.1. South Korea Daratumumab Or Darzalex Market Overview
• 16.2. South Korea Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Daratumumab Or Darzalex Market

• 17.1. Western Europe Daratumumab Or Darzalex Market Overview
• 17.2. Western Europe Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Daratumumab Or Darzalex Market

• 18.1. UK Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Daratumumab Or Darzalex Market

• 19.1. Germany Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Daratumumab Or Darzalex Market

• 20.1. France Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Daratumumab Or Darzalex Market

• 21.1. Eastern Europe Daratumumab Or Darzalex Market Overview
• 21.2. Eastern Europe Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Daratumumab Or Darzalex Market

• 22.1. North America Daratumumab Or Darzalex Market Overview
• 22.2. North America Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Daratumumab Or Darzalex Market

• 23.1. USA Daratumumab Or Darzalex Market Overview
• 23.2. USA Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Daratumumab Or Darzalex Market

• 24.1. Canada Daratumumab Or Darzalex Market Overview
• 24.2. Canada Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Daratumumab Or Darzalex Market

• 25.1. South America Daratumumab Or Darzalex Market Overview
• 25.2. South America Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Daratumumab Or Darzalex Market

• 26.1. Middle East Daratumumab Or Darzalex Market Overview
• 26.2. Middle East Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Daratumumab Or Darzalex Market

• 27.1. Africa Daratumumab Or Darzalex Market Overview
• 27.2. Africa Daratumumab Or Darzalex Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Daratumumab Or Darzalex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Daratumumab Or Darzalex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Daratumumab Or Darzalex Market Competitive Landscape And Company Profiles

• 28.1. Daratumumab Or Darzalex Market Competitive Landscape
• 28.2. Daratumumab Or Darzalex Market Company Profiles
  • 28.2.1. Genmab A/S Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. Janssen Biotech Inc. Overview, Products and Services, Strategy and Financial Analysis

29. Global Daratumumab Or Darzalex Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Daratumumab Or Darzalex Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Daratumumab Or Darzalex Market

32. Recent Developments In The Daratumumab Or Darzalex Market

33. Daratumumab Or Darzalex Market High Potential Countries, Segments and Strategies

• 33.1 Daratumumab Or Darzalex Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Daratumumab Or Darzalex Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Daratumumab Or Darzalex Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer

관련자료